Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5-alpha reductase type II is an enzyme that catalyzes the irreversible conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen, using NADPH as a cofactor. This reaction is crucial for male sexual differentiation and development, particularly in the formation of external genitalia before birth. It is encoded by the SRD5A2 gene.
Inhibition of 5-alpha reductase type II, reducing DHT production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-alpha Reductase Type II (5α-Reductase Type II).